Loading…

Successful utilization of topical trametinib for neurofibromatosis type I‐associated plexiform neurofibroma

An 11‐year‐old female with neurofibromatosis type 1 (NF‐1) and history of optic glioma presented with a progressive cutaneous plexiform neurofibroma of the breast. The lesion was treated with topical application of a mitogen‐activated protein kinase inhibitor, trametinib, resulting in stable, non‐pr...

Full description

Saved in:

Bibliographic Details
Published in:	Pediatric dermatology 2024-11, Vol.41 (6), p.1246-1247
Main Authors:	Melnikov, Leonid, Brichta, Lars, Schloemer, Nathan J.
Format:	Article
Language:	English
Subjects:	administration Administration, Topical Child dermatology Female Humans Inhibitor drugs Neurofibroma, Plexiform - drug therapy Neurofibromatosis Neurofibromatosis 1 - complications Neurofibromatosis 1 - drug therapy pediatric Plexiform neurofibroma Protein Kinase Inhibitors - therapeutic use Pyridones - therapeutic use Pyrimidinones - therapeutic use Recklinghausen's disease Skin Neoplasms - drug therapy therapeutic topical Topical application trametinib
Citations:	Items that this one cites
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by
cites	cdi_FETCH-LOGICAL-c2430-d429b2c43142d534784c657402b786e8acfc0ae4a1d40c2cde89920d9e0f81f73
container_end_page	1247
container_issue	6
container_start_page	1246
container_title	Pediatric dermatology
container_volume	41
creator	Melnikov, Leonid Brichta, Lars Schloemer, Nathan J.
description	An 11‐year‐old female with neurofibromatosis type 1 (NF‐1) and history of optic glioma presented with a progressive cutaneous plexiform neurofibroma of the breast. The lesion was treated with topical application of a mitogen‐activated protein kinase inhibitor, trametinib, resulting in stable, non‐progression cutaneous plexiform neurofibroma for greater than 2 years. This case demonstrates the potential application of topical trametinib for NF1‐associated superficial cutaneous plexiform neurofibroma without the toxicities associated with systemic treatment.
doi_str_mv	10.1111/pde.15710
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3100275928</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3130554311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2430-d429b2c43142d534784c657402b786e8acfc0ae4a1d40c2cde89920d9e0f81f73</originalsourceid><addsrcrecordid>eNp10c9q3DAQBnBRGprNtoe-QBHkkhycHcnyv2PZbpKFhQTSno0sj0DBtlxJJt2c8gh5xj5JlOw2kEDnMpcfH8N8hHxlcMbiLMYWz1hWMPhAZizjWcJEAR_JDIo0T0oQ-SE58v4WAMo8Z5_IYVpxHl0-I_3NpBR6r6eOTsF05l4GYwdqNQ12NEp2NDjZYzCDaai2jg44OatN42wvg_XG07Adka7_PjxK760yMmBLxw7_mMj7N_4zOdCy8_hlv-fk1_nq5_Iy2VxdrJffN4niIoWkFbxquBIpE7zNUlGUQuVZIYA3RZljKZVWIFFI1gpQXLVYVhWHtkLQJdNFOicnu9zR2d8T-lD3xivsOjmgnXydMgBeZBUvIz1-R2_t5IZ4XVQpZFm8gkV1ulPKWe8d6np0ppduWzOonzuoYwf1SwfRftsnTk2P7av89_QIFjtwZzrc_j-pvv6x2kU-Abi1ksM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3130554311</pqid></control><display><type>article</type><title>Successful utilization of topical trametinib for neurofibromatosis type I‐associated plexiform neurofibroma</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Melnikov, Leonid ; Brichta, Lars ; Schloemer, Nathan J.</creator><creatorcontrib>Melnikov, Leonid ; Brichta, Lars ; Schloemer, Nathan J.</creatorcontrib><description>An 11‐year‐old female with neurofibromatosis type 1 (NF‐1) and history of optic glioma presented with a progressive cutaneous plexiform neurofibroma of the breast. The lesion was treated with topical application of a mitogen‐activated protein kinase inhibitor, trametinib, resulting in stable, non‐progression cutaneous plexiform neurofibroma for greater than 2 years. This case demonstrates the potential application of topical trametinib for NF1‐associated superficial cutaneous plexiform neurofibroma without the toxicities associated with systemic treatment.</description><identifier>ISSN: 0736-8046</identifier><identifier>ISSN: 1525-1470</identifier><identifier>EISSN: 1525-1470</identifier><identifier>DOI: 10.1111/pde.15710</identifier><identifier>PMID: 39225256</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>administration ; Administration, Topical ; Child ; dermatology ; Female ; Humans ; Inhibitor drugs ; Neurofibroma, Plexiform - drug therapy ; Neurofibromatosis ; Neurofibromatosis 1 - complications ; Neurofibromatosis 1 - drug therapy ; pediatric ; Plexiform neurofibroma ; Protein Kinase Inhibitors - therapeutic use ; Pyridones - therapeutic use ; Pyrimidinones - therapeutic use ; Recklinghausen's disease ; Skin Neoplasms - drug therapy ; therapeutic ; topical ; Topical application ; trametinib</subject><ispartof>Pediatric dermatology, 2024-11, Vol.41 (6), p.1246-1247</ispartof><rights>2024 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2430-d429b2c43142d534784c657402b786e8acfc0ae4a1d40c2cde89920d9e0f81f73</cites><orcidid>0000-0001-9103-609X ; 0009-0007-5596-6776</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39225256$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Melnikov, Leonid</creatorcontrib><creatorcontrib>Brichta, Lars</creatorcontrib><creatorcontrib>Schloemer, Nathan J.</creatorcontrib><title>Successful utilization of topical trametinib for neurofibromatosis type I‐associated plexiform neurofibroma</title><title>Pediatric dermatology</title><addtitle>Pediatr Dermatol</addtitle><description>An 11‐year‐old female with neurofibromatosis type 1 (NF‐1) and history of optic glioma presented with a progressive cutaneous plexiform neurofibroma of the breast. The lesion was treated with topical application of a mitogen‐activated protein kinase inhibitor, trametinib, resulting in stable, non‐progression cutaneous plexiform neurofibroma for greater than 2 years. This case demonstrates the potential application of topical trametinib for NF1‐associated superficial cutaneous plexiform neurofibroma without the toxicities associated with systemic treatment.</description><subject>administration</subject><subject>Administration, Topical</subject><subject>Child</subject><subject>dermatology</subject><subject>Female</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Neurofibroma, Plexiform - drug therapy</subject><subject>Neurofibromatosis</subject><subject>Neurofibromatosis 1 - complications</subject><subject>Neurofibromatosis 1 - drug therapy</subject><subject>pediatric</subject><subject>Plexiform neurofibroma</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyridones - therapeutic use</subject><subject>Pyrimidinones - therapeutic use</subject><subject>Recklinghausen's disease</subject><subject>Skin Neoplasms - drug therapy</subject><subject>therapeutic</subject><subject>topical</subject><subject>Topical application</subject><subject>trametinib</subject><issn>0736-8046</issn><issn>1525-1470</issn><issn>1525-1470</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp10c9q3DAQBnBRGprNtoe-QBHkkhycHcnyv2PZbpKFhQTSno0sj0DBtlxJJt2c8gh5xj5JlOw2kEDnMpcfH8N8hHxlcMbiLMYWz1hWMPhAZizjWcJEAR_JDIo0T0oQ-SE58v4WAMo8Z5_IYVpxHl0-I_3NpBR6r6eOTsF05l4GYwdqNQ12NEp2NDjZYzCDaai2jg44OatN42wvg_XG07Adka7_PjxK760yMmBLxw7_mMj7N_4zOdCy8_hlv-fk1_nq5_Iy2VxdrJffN4niIoWkFbxquBIpE7zNUlGUQuVZIYA3RZljKZVWIFFI1gpQXLVYVhWHtkLQJdNFOicnu9zR2d8T-lD3xivsOjmgnXydMgBeZBUvIz1-R2_t5IZ4XVQpZFm8gkV1ulPKWe8d6np0ppduWzOonzuoYwf1SwfRftsnTk2P7av89_QIFjtwZzrc_j-pvv6x2kU-Abi1ksM</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Melnikov, Leonid</creator><creator>Brichta, Lars</creator><creator>Schloemer, Nathan J.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9103-609X</orcidid><orcidid>https://orcid.org/0009-0007-5596-6776</orcidid></search><sort><creationdate>202411</creationdate><title>Successful utilization of topical trametinib for neurofibromatosis type I‐associated plexiform neurofibroma</title><author>Melnikov, Leonid ; Brichta, Lars ; Schloemer, Nathan J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2430-d429b2c43142d534784c657402b786e8acfc0ae4a1d40c2cde89920d9e0f81f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>administration</topic><topic>Administration, Topical</topic><topic>Child</topic><topic>dermatology</topic><topic>Female</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Neurofibroma, Plexiform - drug therapy</topic><topic>Neurofibromatosis</topic><topic>Neurofibromatosis 1 - complications</topic><topic>Neurofibromatosis 1 - drug therapy</topic><topic>pediatric</topic><topic>Plexiform neurofibroma</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyridones - therapeutic use</topic><topic>Pyrimidinones - therapeutic use</topic><topic>Recklinghausen's disease</topic><topic>Skin Neoplasms - drug therapy</topic><topic>therapeutic</topic><topic>topical</topic><topic>Topical application</topic><topic>trametinib</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Melnikov, Leonid</creatorcontrib><creatorcontrib>Brichta, Lars</creatorcontrib><creatorcontrib>Schloemer, Nathan J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Melnikov, Leonid</au><au>Brichta, Lars</au><au>Schloemer, Nathan J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful utilization of topical trametinib for neurofibromatosis type I‐associated plexiform neurofibroma</atitle><jtitle>Pediatric dermatology</jtitle><addtitle>Pediatr Dermatol</addtitle><date>2024-11</date><risdate>2024</risdate><volume>41</volume><issue>6</issue><spage>1246</spage><epage>1247</epage><pages>1246-1247</pages><issn>0736-8046</issn><issn>1525-1470</issn><eissn>1525-1470</eissn><abstract>An 11‐year‐old female with neurofibromatosis type 1 (NF‐1) and history of optic glioma presented with a progressive cutaneous plexiform neurofibroma of the breast. The lesion was treated with topical application of a mitogen‐activated protein kinase inhibitor, trametinib, resulting in stable, non‐progression cutaneous plexiform neurofibroma for greater than 2 years. This case demonstrates the potential application of topical trametinib for NF1‐associated superficial cutaneous plexiform neurofibroma without the toxicities associated with systemic treatment.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39225256</pmid><doi>10.1111/pde.15710</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0001-9103-609X</orcidid><orcidid>https://orcid.org/0009-0007-5596-6776</orcidid></addata></record>
fulltext	fulltext
identifier	ISSN: 0736-8046
ispartof	Pediatric dermatology, 2024-11, Vol.41 (6), p.1246-1247
issn	0736-8046 1525-1470 1525-1470
language	eng
recordid	cdi_proquest_miscellaneous_3100275928
source	Wiley-Blackwell Read & Publish Collection
subjects	administration Administration, Topical Child dermatology Female Humans Inhibitor drugs Neurofibroma, Plexiform - drug therapy Neurofibromatosis Neurofibromatosis 1 - complications Neurofibromatosis 1 - drug therapy pediatric Plexiform neurofibroma Protein Kinase Inhibitors - therapeutic use Pyridones - therapeutic use Pyrimidinones - therapeutic use Recklinghausen's disease Skin Neoplasms - drug therapy therapeutic topical Topical application trametinib
title	Successful utilization of topical trametinib for neurofibromatosis type I‐associated plexiform neurofibroma
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T07%3A52%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20utilization%20of%20topical%20trametinib%20for%20neurofibromatosis%20type%20I%E2%80%90associated%20plexiform%20neurofibroma&rft.jtitle=Pediatric%20dermatology&rft.au=Melnikov,%20Leonid&rft.date=2024-11&rft.volume=41&rft.issue=6&rft.spage=1246&rft.epage=1247&rft.pages=1246-1247&rft.issn=0736-8046&rft.eissn=1525-1470&rft_id=info:doi/10.1111/pde.15710&rft_dat=%3Cproquest_cross%3E3130554311%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2430-d429b2c43142d534784c657402b786e8acfc0ae4a1d40c2cde89920d9e0f81f73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3130554311&rft_id=info:pmid/39225256&rfr_iscdi=true